A Composite MR NeuroImaging Marker for Alzheimer's Disease
A Composite MR NeuroImaging Marker for Alzheimer's Disease
批准号:
8217106
负责人:
Shi-Jiang Li
金额:
$29.65万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-07-01 至 2014-01-31
关键词:
AffectAgeAge-associated memory impairmentAging-Related ProcessAlzheimer&aposs DiseaseAmericanAmyloid depositionAtrophicBiological MarkersBrainBrain InjuriesCerebrospinal FluidCerebrovascular CirculationCharacteristicsClinicalCognitiveDementiaDiagnosisDiseaseDisease ProgressionEarly DiagnosisFrontotemporal DementiaFunctional Magnetic Resonance ImagingGenotypeGlucoseGoalsHealthHeterogeneityImaging technologyIndividualLigand BindingLiteratureLongitudinal StudiesMagnetic Resonance ImagingMeasurementMeasuresMedialMethodsMolecularPathogenesisPatientsPatternPerfusionPhasePlasmaPositron-Emission TomographyPresenile Alzheimer DementiaPreventionRelative (related person)ResearchResearch PersonnelResearch Project GrantsRestRiskSenile PlaquesSensitivity and SpecificitySignaling ProteinStagingSymptomsTechniquesTemporal LobeTestingTimeVariantVascular Dementiaassociation cortexbasedata acquisitiondisease characteristicdisorder preventioneffective therapyindexinginnovationinterestmild neurocognitive impairmentneuroimagingnew technologynormal agingpre-clinical
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This proposal is a competing renewal of our current research project. Neuropathological changes related to Alzheimer's Disease (AD) may begin 20 to 30 years before the onset of clinical symptoms in individuals at great risk. AD affects an estimated 4.5 million Americans and is expected to affect as many as 16 million Americans by 2050, as the baby boomers reach the age at which they are most at risk. It is of major concern to explore and develop new technologies for the early detection of AD in order to facilitate disease prevention, diagnosis, and effective treatment. The goal of this RO1 proposal is to develop an innovative imaging technology for the early detection of AD. We propose a new composite MRI Neuroimaging (MRN) Index, obtained by quantitatively combining two fMRI measurements: Functional Connectivity Index (FCI) and Regional Cerebral Blood Flow (rCBF)-Perfusion Deficits at the resting-state condition. To validate this Index as a marker, we first test whether it can cross-sectionally distinguish mild AD from cognitive normal (CN) subjects and distinguish mild AD from other types of non-AD dementia, such as frontotemporal dementia (FTD) and vascular dementia (VaD). Second, we test whether the MRN Index can retroactively predict mild cognitive impairment (MCI) subjects who converted to AD from those who did not. Third, we will determine the dynamic characteristics of the MRN Index in predicting the onset of AD dementia in MCI subjects during the longitudinal studies. PUBLIC HEALTH RELEVANCE: This proposal is a competing renewal of our current research project. Neuropathological changes related to Alzheimer's Disease (AD) may begin 20 to 30 years before the onset of clinical symptoms in individuals at great risk. AD affects an estimated 4.5 million Americans and is expected to affect as many as 16 million Americans by 2050, as the baby boomers reach the age at which they are most at risk. It is of major concern to explore and develop new technologies for the early detection of AD in order to facilitate disease prevention, diagnosis, and effective treatment. The goal of this proposal is to develop an innovative imaging technology for the early detection of AD. We propose a new composite MRI Neuroimaging (MRN) Index, obtained by quantitatively combining two functional MRI measurements: Functional Connectivity Index (FCI) and Regional Cerebral Blood Flow (rCBF)-Perfusion Deficits at the resting-state condition. We will employ the MRN index to distinguish mild cognitive impaired subjects who are destined to develop AD from individuals evidencing the normal aging processes or converting to different types of dementia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Network-Level Mechanisms for Preclinical Alzheimer?s Disease Development
-
批准号:9371548
-
项目类别:
-
资助金额:$22.7万
-
财政年份:2017
-
负责人:Shi-Jiang Li
-
依托单位:
Network-Level Mechanisms for Preclinical Alzheimer?s Disease Development
-
批准号:9527726
-
项目类别:
-
资助金额:$18.85万
-
财政年份:2017
-
负责人:Shi-Jiang Li
-
依托单位:
NEUROBIOLOGY OF COCAINE ABUSE DETECTED BY FUNCTIONAL MRI
-
批准号:7375060
-
项目类别:
-
资助金额:$1.22万
-
财政年份:2005
-
负责人:Shi-Jiang Li
-
依托单位:
NEUROBIOLOGY OF COCAINE ABUSE DETECTED BY FUNCTIONAL MRI
-
批准号:7201231
-
项目类别:
-
资助金额:$1.01万
-
财政年份:2004
-
负责人:Shi-Jiang Li
-
依托单位:
Development of fMRI Methods for Neurpharmacology
-
批准号:6708671
-
项目类别:
-
资助金额:$33.39万
-
财政年份:2003
-
负责人:Shi-Jiang Li
-
依托单位:
Development of fMRI Methods for Neurpharmacology
-
批准号:7096541
-
项目类别:
-
资助金额:$32.96万
-
财政年份:2003
-
负责人:Shi-Jiang Li
-
依托单位:
Neurobiology of Cocaine Abuse Detected by Functional MRI
-
批准号:6980822
-
项目类别:
-
资助金额:$6.0万
-
财政年份:2003
-
负责人:Shi-Jiang Li
-
依托单位:
Development of fMRI Methods for Neuropharmacology
-
批准号:7268864
-
项目类别:
-
资助金额:$32.0万
-
财政年份:2003
-
负责人:Shi-Jiang Li
-
依托单位:
Development of fMRI Methods for Neurpharmacology
-
批准号:6929933
-
项目类别:
-
资助金额:$33.75万
-
财政年份:2003
-
负责人:Shi-Jiang Li
-
依托单位:
Development of fMRI Methods for Neurpharmacology
-
批准号:6797772
-
项目类别:
-
资助金额:$33.75万
-
财政年份:2003
-
负责人:Shi-Jiang Li
-
依托单位:
An FMRI Index as a Risk Marker for Alzheimer's Disease
-
批准号:7082038
-
项目类别:
-
资助金额:$34.63万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
An FMRI Index as a Risk Marker for Alzheimer's Disease
-
批准号:6545584
-
项目类别:
-
资助金额:$35.46万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
A Composite MR NeuroImaging Marker for Alzheimer's Disease
-
批准号:7651863
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
An FMRI Index as a Risk Marker for Alzheimer's Disease
-
批准号:6759342
-
项目类别:
-
资助金额:$35.46万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
A Composite MR NeuroImaging Marker for Alzheimer's Disease
-
批准号:7769925
-
项目类别:
-
资助金额:$30.85万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
An FMRI Index as a Risk Marker for Alzheimer's Disease
-
批准号:6905599
-
项目类别:
-
资助金额:$35.63万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
An FMRI Index as a Risk Marker for Alzheimer's Disease
-
批准号:6640352
-
项目类别:
-
资助金额:$35.63万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
A Composite MR NeuroImaging Marker for Alzheimer's Disease
-
批准号:8019994
-
项目类别:
-
资助金额:$29.65万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
Bruker Biospec 9.4T/40cm Bore MRI System
-
批准号:6440884
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
A Composite MR NeuroImaging Marker for Alzheimer's Disease
-
批准号:8423006
-
项目类别:
-
资助金额:$28.02万
-
财政年份:2002
-
负责人:Shi-Jiang Li
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: